Literature DB >> 18336593

Regulation of galectin-3 function in mucosal fibroblasts: potential role in mucosal inflammation.

E Lippert1, M Gunckel, J Brenmoehl, F Bataille, W Falk, J Scholmerich, F Obermeier, G Rogler.   

Abstract

Recently we identified galectin-3 (gal-3), which is secreted by colonic epithelial cells (CEC), to be a strong activator of colonic lamina propria fibroblasts (CLPF). Modulation of CLPF function may play a role during stricture and fistula formation in inflammatory bowel disease (IBD). Therefore, we investigated further the expression of gal-3 and effects on CLPF. The aim of this study is to perform a direct comparison of gal-3 between tissue from healthy controls and from patients with either Crohn's disease (CD) or ulcerative colitis (UC). CEC, CLPF and intestinal macrophages (IMAC) were isolated from control and IBD colonic tissue. Interleukin-8 secretion as a readout of CLPF activation was quantified by enzyme-linked immunosorbent assay. Gal-3 in cell cultures and tissue samples was evaluated by Western blot, immunofluorescence and immunohistochemistry. CLPF-migration was assayed in the 48-well modified Boyden chamber. Gal-3 expression was found in all segments of the colon. In the terminal ileum, less gal-3 was found compared with the colon. Immunohistochemistry and immunofluorescence revealed a homogenous distribution of gal-3 in CEC and IMAC of control mucosa and UC. However, significantly less gal-3 was found in IMAC from CD patients. In CD fistulae and stenoses, gal-3 expression was reduced significantly and barely detectable. In co-incubation studies lactose reduced significantly the CLPF-stimulatory potential of gal-3, indicating that the C-terminal domain of gal-3 is responsible for CLPF activation. Gal-3 stimulated CLPF migration in CLPF derived from fistulae. In conclusion, gal-3 expression is down-regulated in CD-fistulae and stenoses as well as in IMAC in CD patients. Gal-3 induces migration of CLPF derived from fistulae. Its role for stricture and fistula formation warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18336593      PMCID: PMC2384104          DOI: 10.1111/j.1365-2249.2008.03618.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  58 in total

1.  The constitutive expression of galectin-3 is downregulated in the intestinal epithelia of Crohn's disease patients, and tumour necrosis factor alpha decreases the level of galectin-3-specific mRNA in HCT-8 cells.

Authors:  Erika Jensen-Jarolim; Regina Gscheidlinger; Georg Oberhuber; Czilla Neuchrist; Trevor Lucas; Giovanna Bises; Christian Radauer; Martin Willheim; Otto Scheiner; Fu-Tong Liu; George Boltz-Nitulescu
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-02       Impact factor: 2.566

2.  Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia.

Authors:  Sachiko Sato; Nathalie Ouellet; Isabelle Pelletier; Marie Simard; Ann Rancourt; Michel G Bergeron
Journal:  J Immunol       Date:  2002-02-15       Impact factor: 5.422

3.  Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest.

Authors:  Tadashi Yoshii; Tomoharu Fukumori; Yuichiro Honjo; Hidenori Inohara; Hyeong-Reh Choi Kim; Avraham Raz
Journal:  J Biol Chem       Date:  2001-11-27       Impact factor: 5.157

4.  Anti-Galectin-3 IgG autoantibodies in patients with Crohn's disease characterized by means of phage display peptide libraries.

Authors:  E Jensen-Jarolim; C Neumann; G Oberhuber; R Gscheidlinger; C Neuchrist; W Reinisch; R I Zuberi; E Penner; F T Liu; G Boltz-Nitulescu
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

5.  Galectin-1 and galectin-3 in chronic pancreatitis.

Authors:  L Wang; H Friess; Z Zhu; L Frigeri; A Zimmermann; M Korc; P O Berberat; M W Büchler
Journal:  Lab Invest       Date:  2000-08       Impact factor: 5.662

6.  Immunohistochemical detection of galectin-3 in canine gastric carcinomas.

Authors:  H J Woo; H G Joo; S W Song; Y S Sohn; C Chae
Journal:  J Comp Pathol       Date:  2001 Feb-Apr       Impact factor: 1.311

7.  Human galectin-3 is a novel chemoattractant for monocytes and macrophages.

Authors:  H Sano; D K Hsu; L Yu; J R Apgar; I Kuwabara; T Yamanaka; M Hirashima; F T Liu
Journal:  J Immunol       Date:  2000-08-15       Impact factor: 5.422

8.  Shuttling of galectin-3 between the nucleus and cytoplasm.

Authors:  Peter J Davidson; Michael J Davis; Ronald J Patterson; Marie-Anne Ripoche; Françoise Poirier; John L Wang
Journal:  Glycobiology       Date:  2002-05       Impact factor: 4.313

9.  Galectin-3 stimulates cell proliferation.

Authors:  H Inohara; S Akahani; A Raz
Journal:  Exp Cell Res       Date:  1998-12-15       Impact factor: 3.905

10.  Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients.

Authors:  Julia Brenmoehl; Hans Herfarth; Thomas Glück; Franz Audebert; Stefan Barlage; Gerd Schmitz; Dieter Froehlich; Stefan Schreiber; Jochen Hampe; Jürgen Schölmerich; Ernst Holler; Gerhard Rogler
Journal:  Intensive Care Med       Date:  2007-06-09       Impact factor: 17.440

View more
  14 in total

1.  Myenteric denervation downregulates galectin-1 and -3 expression in gastric carcinogenesis.

Authors:  Cássia F Estofolete; Sérgio Zucoloto; Sonia M Oliani; Ana Cláudia Polli-Lopes; Cristiane D Gil
Journal:  Dig Dis Sci       Date:  2010-12-29       Impact factor: 3.199

Review 2.  Roles of galectins in inflammatory bowel disease.

Authors:  Akira Hokama; Emiko Mizoguchi; Atsushi Mizoguchi
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

Review 3.  Galectin-3 in autoimmunity and autoimmune diseases.

Authors:  Felipe L de Oliveira; Mariele Gatto; Nicola Bassi; Roberto Luisetto; Anna Ghirardello; Leonardo Punzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2015-07-03

Review 4.  Pathophysiology of fistula formation in Crohn's disease.

Authors:  Michael Scharl; Gerhard Rogler
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

5.  Spatiotemporal regulation of galectin-1-induced T-cell death in lamina propria from Crohn's disease and ulcerative colitis patients.

Authors:  Rodrigo Papa-Gobbi; Cecilia I Muglia; Andrés Rocca; Renata Curciarello; Alicia M Sambuelli; Martín Yantorno; Gustavo Correa; Luciano G Morosi; Antonio Di Sabatino; Paolo Biancheri; Thomas T MacDonald; Marta A Toscano; Karina V Mariño; Gabriel A Rabinovich; Guillermo H Docena
Journal:  Apoptosis       Date:  2021-05-12       Impact factor: 4.677

6.  Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease.

Authors:  Peter G Traber; Hsin Chou; Eliezer Zomer; Feng Hong; Anatole Klyosov; Maria-Isabel Fiel; Scott L Friedman
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

7.  Therapy of experimental NASH and fibrosis with galectin inhibitors.

Authors:  Peter G Traber; Eliezer Zomer
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

8.  Immunohistochemical Studies on Galectin Expression in Colectomised Patients with Ulcerative Colitis.

Authors:  Mattias Block; Johan Mölne; Hakon Leffler; Lars Börjesson; Michael E Breimer
Journal:  Biomed Res Int       Date:  2016-01-18       Impact factor: 3.411

Review 9.  Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z.

Authors:  Salvatore Sciacchitano; Luca Lavra; Alessandra Morgante; Alessandra Ulivieri; Fiorenza Magi; Gian Paolo De Francesco; Carlo Bellotti; Leila B Salehi; Alberto Ricci
Journal:  Int J Mol Sci       Date:  2018-01-26       Impact factor: 5.923

10.  The role of Galectin-1 and Galectin-3 in the mucosal immune response to Citrobacter rodentium infection.

Authors:  Renata Curciarello; Alison Steele; Dianne Cooper; Thomas T MacDonald; Laurens Kruidenier; Takahiro Kudo
Journal:  PLoS One       Date:  2014-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.